Update On Seattle Genetics FDA Meeting
TheStreet.com's Adam Feuerstein is tweeting about the Seattle Genetics (NASDAQ: SGEN) FDA meeting.
Feuerstein just tweeted that the FDA panel is moving to questions and voting on Adcetris in ALCL.
The FDA voted 10-0 to recommend accelerated approval of Seattle Genetics' Adcetris.
Shares have been halted all day today.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Adam Feuerstein TheStreet.comNews FDA Media
